EA032117B1 - Применение антитела di17e6 к интегрину альфа-v при производстве лекарственного средства и лечении рака простаты, способ лечения устойчивого к кастрации рака простаты (crpc), способ снижения уровня пса, способ снижения боли, проявляющейся при раке простаты - Google Patents

Применение антитела di17e6 к интегрину альфа-v при производстве лекарственного средства и лечении рака простаты, способ лечения устойчивого к кастрации рака простаты (crpc), способ снижения уровня пса, способ снижения боли, проявляющейся при раке простаты Download PDF

Info

Publication number
EA032117B1
EA032117B1 EA201391147A EA201391147A EA032117B1 EA 032117 B1 EA032117 B1 EA 032117B1 EA 201391147 A EA201391147 A EA 201391147A EA 201391147 A EA201391147 A EA 201391147A EA 032117 B1 EA032117 B1 EA 032117B1
Authority
EA
Eurasian Patent Office
Prior art keywords
όι17ε6
prostate cancer
treatment
antibody
antibodies
Prior art date
Application number
EA201391147A
Other languages
English (en)
Russian (ru)
Other versions
EA201391147A1 (ru
Inventor
Аксель Хоффманн
Генрих Ланнерт
Клаус Бришвайн
Фредерик Кристиан Пипп
Йюрген Райндль
Карин Гролль
Михель Цюльсдорф
Отмар Пфафф
Забине Рааб
Ульрике Дау
Бенуа Дестенав
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201391147A1 publication Critical patent/EA201391147A1/ru
Publication of EA032117B1 publication Critical patent/EA032117B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201391147A 2011-02-11 2012-02-07 Применение антитела di17e6 к интегрину альфа-v при производстве лекарственного средства и лечении рака простаты, способ лечения устойчивого к кастрации рака простаты (crpc), способ снижения уровня пса, способ снижения боли, проявляющейся при раке простаты EA032117B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11001135 2011-02-11
PCT/EP2012/000548 WO2012107211A1 (en) 2011-02-11 2012-02-07 Anti-alpha-v integrin antibody for the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
EA201391147A1 EA201391147A1 (ru) 2014-01-30
EA032117B1 true EA032117B1 (ru) 2019-04-30

Family

ID=45569571

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391147A EA032117B1 (ru) 2011-02-11 2012-02-07 Применение антитела di17e6 к интегрину альфа-v при производстве лекарственного средства и лечении рака простаты, способ лечения устойчивого к кастрации рака простаты (crpc), способ снижения уровня пса, способ снижения боли, проявляющейся при раке простаты

Country Status (23)

Country Link
US (3) US9555110B2 (enExample)
EP (2) EP3415162A1 (enExample)
JP (2) JP6320042B2 (enExample)
KR (2) KR101972533B1 (enExample)
CN (1) CN103347540B (enExample)
AU (2) AU2012216145B2 (enExample)
CA (1) CA2827052C (enExample)
DK (1) DK2672994T3 (enExample)
EA (1) EA032117B1 (enExample)
ES (1) ES2683347T3 (enExample)
HR (1) HRP20181212T1 (enExample)
HU (1) HUE037212T2 (enExample)
IL (1) IL227687B (enExample)
LT (1) LT2672994T (enExample)
MX (2) MX352025B (enExample)
PL (1) PL2672994T3 (enExample)
PT (1) PT2672994T (enExample)
RS (1) RS57524B1 (enExample)
SG (1) SG192667A1 (enExample)
SI (1) SI2672994T1 (enExample)
TR (1) TR201810294T4 (enExample)
WO (1) WO2012107211A1 (enExample)
ZA (1) ZA201306807B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX352025B (es) 2011-02-11 2017-11-07 Merck Patent Gmbh Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.
BR112017005336A2 (pt) 2014-09-17 2017-12-12 Merck Patent Gmbh método de tratamento de cânceres sólidos e/ou metástases dos mesmos, medicamentos com essa finalidade e método para prever o resultado clínico de tratamento de cânceres sólidos e/ou metástases dos mesmos
CN106714835A (zh) 2014-09-17 2017-05-24 默克专利股份公司 治疗骨转移疾病的方法、其药物以及预测治疗骨转移疾病的临床结果的方法
AU2016360661B2 (en) * 2015-11-23 2023-12-14 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
EP4637731A1 (en) 2022-12-21 2025-10-29 Gilead Sciences, Inc. Combination therapy for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011162933A1 (en) * 2010-06-04 2011-12-29 Immunogen, Inc. Anti-integrin immunoconjugate dosing regimens

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
DK0719859T3 (da) 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
AU2003298783B2 (en) 2002-11-26 2010-11-04 Abbvie Biotherapeutics Inc. Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
CN1953768B (zh) 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
US8202465B2 (en) 2004-11-03 2012-06-19 Honeywell International Inc. Preferential curing technique in compression molding of fiber reinforced composites
US20070025889A1 (en) 2005-07-28 2007-02-01 Pcbu Business Services, Inc. Reactors, reactor assemblies and production processes
DE102005062440B4 (de) 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
EP1973569B1 (en) 2006-01-18 2013-05-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
WO2008008435A2 (en) 2006-07-14 2008-01-17 Rutgers, The State University Methods, systems, and compositions for extracellular matrix production
ES2395799T3 (es) * 2007-07-17 2013-02-15 Merck Patent Gmbh Anticuerpos híbridos anti- integrina alfa V modificados genéticamente
US20110177155A1 (en) 2007-08-21 2011-07-21 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells
EP2706358A3 (en) * 2008-12-23 2014-05-07 Merck Patent GmbH Biomarkers for inhibitors with anti-angiogenic activity
AU2010285265B2 (en) 2009-08-19 2015-05-21 Merck Patent Gmbh Antibodies for the detection of integrin complexes in FFPE material
JP2013510804A (ja) 2009-11-13 2013-03-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 化学療法剤を装荷したナノ粒子に結合した抗インテグリン抗体
MX352025B (es) 2011-02-11 2017-11-07 Merck Patent Gmbh Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.
JP6035716B2 (ja) 2011-08-26 2016-11-30 ソニー株式会社 情報処理システム及び情報処理方法
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011162933A1 (en) * 2010-06-04 2011-12-29 Immunogen, Inc. Anti-integrin immunoconjugate dosing regimens

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"A study to determine the safety, tolerability, pharmacokinetics and dynamic effects of different doses of the study drug EM525797 in prostate cancer", Clinicaltrials. gov, 11 August 2009 (2009-08-11), XP002675310, Retrieved from the Internet: URL:http://www.clinicaltrials.gov/ct2/show/NCT00958477?term=emd525797&rank=3, [retrieved on 2012-05-04], the whole document *
BISANZ, K. YU, J. EDLUND, M. SPOHN, B. HUNG, M.C. CHUNG, L.W.K. HSIEH, C.L.: "Targeting ECM-Integrin Interaction with Liposome-Encapsulated Small Interfering RNAs Inhibits the Growth of Human Prostate Cancer in a Bone Xenograft Imaging Model", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 12, no. 4, 1 October 2005 (2005-10-01), GB, pages 634 - 643, XP005078442, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2005.05.012 *
JAY S. DESGROSELLIER, CHERESH DAVID A.: "Integrins in cancer: biological implications and therapeutic opportunities", NATURE REVIEWS CANCER, NATURE PUB. GROUP, vol. 10, no. 1, 1 January 2010 (2010-01-01), pages 9 - 22, XP055016659, ISSN: 1474175X, DOI: 10.1038/nrc2748 *
JEFFREY A. NEMETH ; MICHAEL L. CHER ; ZHAO ZHOU ; CHADWICK MULLINS ; SUNITA BHAGAT ; MOHIT TRIKHA: "Inhibition of αvβ3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases", CLINICAL & EXPERIMENTAL METASTASIS ; OFFICIAL JOURNAL OF THEMETASTASIS RESEARCH SOCIETY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 20, no. 5, 1 September 2003 (2003-09-01), Do, pages 413 - 420, XP019235691, ISSN: 1573-7276, DOI: 10.1023/A:1025461507027 *
MILLARD M, ODDE S, NEAMATI N: "Integrin Targeted Therapeutics", THERANOSTICS, IVYSPRING INTERNATIONAL PUBLISHER, AU, vol. 1, 17 February 2011 (2011-02-17), AU, pages 154 - 188, XP002675313, ISSN: 1838-7640, DOI: 10.7150/thno/v01p0154 *
UNKNOWN: "Product data sheet of Anti-Integrin alpha(v) (Ab-1) Mouse mAb (272-17E6) and corresponding safety data sheet", INTERNET CITATION, [Online], pages 1-2,1, XP002615477, Retrieved from the Internet: URL:http://www.merck-chemicals.com/usa/life-science-research/anti-integrin-alpha-v-ab-1-mouse-mab-272-17e6/EMD_BIO-407286/p_JR6b.s1LruAAAAEWZmEfVhTm>, [retrieved on 2010-12-23], the whole document *
WAGNER, S. ; ROTHWEILER, F. ; ANHORN, M.G. ; SAUER, D. ; RIEMANN, I. ; WEISS, E.C. ; KATSEN-GLOBA, A. ; MICHAELIS, M. ; CINATL, J.: "Enhanced drug targeting by attachment of an anti +/-v integrin antibody to doxorubicin loaded human serum albumin nanoparticles", BIOMATERIALS., ELSEVIER SCIENCE PUBLISHERS BV., BARKING., GB, vol. 31, no. 8, 1 March 2010 (2010-03-01), GB, pages 2388 - 2398, XP026870608, ISSN: 0142-9612 *
Wirth et al.: European J. Canc., vol. 47, no. supp. 1, 23 September 2011 (2011-09-23), page S488, XP002675312, DOI: http://dx.doi.org/10.1016/50959-8049(11)71, 964-5, Retrieved from the Internet: URL:http://www.sciencedirect.com/science/article/pii/S0959804911719645, [retrieved on 2012-05-04], the whole document *
Wirth et al.: J. Clin. Oncol., vol. 29 suppl., E15060, 20 May 2011 (2011-05-20), XP002675311, Retrieved from the Internet: URL:http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/e15060?sid=e353144d-d8a6-4f66-8489-615fc0e23f59, [retrieved on 2012-05-04], the whole document *

Also Published As

Publication number Publication date
IL227687A0 (en) 2013-09-30
CN103347540B (zh) 2016-05-25
MX2013009062A (es) 2013-10-01
WO2012107211A1 (en) 2012-08-16
AU2017200998A1 (en) 2017-03-09
US20170218070A1 (en) 2017-08-03
ZA201306807B (en) 2014-05-28
DK2672994T3 (en) 2018-07-16
EA201391147A1 (ru) 2014-01-30
CN103347540A (zh) 2013-10-09
US9555110B2 (en) 2017-01-31
IL227687B (en) 2019-02-28
HRP20181212T1 (hr) 2018-10-05
JP2017066156A (ja) 2017-04-06
KR20140012087A (ko) 2014-01-29
CA2827052C (en) 2022-08-16
HUE037212T2 (hu) 2018-08-28
EP2672994B1 (en) 2018-05-09
AU2012216145B2 (en) 2016-11-17
PT2672994T (pt) 2018-10-22
AU2012216145A1 (en) 2013-09-26
SG192667A1 (en) 2013-09-30
TR201810294T4 (tr) 2018-08-27
KR20190044696A (ko) 2019-04-30
MX385144B (es) 2025-03-14
MX352025B (es) 2017-11-07
EP2672994A1 (en) 2013-12-18
KR102103701B1 (ko) 2020-04-23
US20140086908A1 (en) 2014-03-27
JP2014510047A (ja) 2014-04-24
ES2683347T3 (es) 2018-09-26
SI2672994T1 (sl) 2018-09-28
LT2672994T (lt) 2018-07-25
KR101972533B1 (ko) 2019-08-26
PL2672994T3 (pl) 2018-11-30
CA2827052A1 (en) 2012-08-16
HK1190094A1 (zh) 2014-06-27
JP6488273B2 (ja) 2019-03-20
EP3415162A1 (en) 2018-12-19
RS57524B1 (sr) 2018-10-31
AU2017200998B2 (en) 2018-08-09
JP6320042B2 (ja) 2018-05-09
US20190263913A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
JP6488273B2 (ja) 前立腺癌治療のための抗アルファ−ｖインテグリン抗体
CN104661679A (zh) 包含双重血管生成素-2/Dll4结合物和抗VEGF药剂的药物组合
US20210046181A1 (en) Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation
JP2015502975A (ja) ヒト成長ホルモン受容体アンタゴニスト抗体およびその使用方法
EA037709B1 (ru) Способ лечения невропатической боли
US20210130403A1 (en) Inhibitors of metastasis
EP3261672B1 (en) Molecules disrupting pyruvate kinase m2 and integrin interaction and uses thereof
US11674959B2 (en) Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
HK1190094B (en) Anti-alpha-v integrin antibody for the treatment of prostate cancer
WO2022272180A2 (en) Mmp-14 antibodies and uses thereof
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
WO2023278491A1 (en) Mmp-9 antibodies and uses thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ MD TM